Cathepsin K as a biomarker of bone involvement in type 1 Gaucher disease

Grabowski, 2008, Phenotype, diagnosis and treatment of Gaucher's disease, Lancet, 372, 1263, 10.1016/S0140-6736(08)61522-6 Brady, 1965, Metabolism of glucocerebrosidases. II. Evidence of an enzymatic deficiency in Gaucher's disease, Biochem Biophys Res Commun, 18, 211, 10.1016/0006-291X(65)90743-6 Beutler, 2001, Gaucher disease, 3635 Biegstraaten, 2008, Non neuronopathic Gaucher disease reconsidered. Prevalence of neurological manifestations in Dutch cohort of type I Gaucher disease patients and a systematic review of the literature, J Inherit Metab Dis, 1, 337, 10.1007/s10545-008-0832-y Van Dussen, 2011, Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease, J Clin Endocrinol Metab, 96, 2194, 10.1210/jc.2011-0162 Weinreb, 2007, The bone in Gaucher disease, Eur Musculoskelet Rev, 1, 33 Maas, 2003, Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical MR imaging-initial experience, Radiology, 229, 554, 10.1148/radiol.2292020296 Boven, 2004, Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages, Am J Clin Pathol, 122, 356, 10.1309/BG5VA8JRDQH1M7HN Allen, 1997, Proinflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-1, Quart J Med, 90, 19, 10.1093/qjmed/90.1.19 Altarescu, 2005, TNF-alpha levels and TNF-alpha gene polymorphism in type 1 Gaucher disease, Cytokine, 31, 149, 10.1016/j.cyto.2005.03.006 Van Breemen, 2007, Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease, Biochim Biophys Acta, 1772, 788, 10.1016/j.bbadis.2007.04.002 Wenstrup, 2002, Skeletal aspect of Gaucher disease: a review, Br J Radiol, 75, A2, 10.1259/bjr.75.suppl_1.750002 Kafienah, 1998, Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix, Biochem J, 331, 727, 10.1042/bj3310727 Troen, 2004, The role of cathepsin K in normal bone resorption, Drug News Perspect, 17, 19, 10.1358/dnp.2004.17.1.829022 Garnero, 1998, The collagenolytic activity of cathepsin K is unique among mammalian proteinases, J Biol Chem, 273, 32347, 10.1074/jbc.273.48.32347 Moran, 2000, Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K, Blood, 96, 1969, 10.1182/blood.V96.5.1969 Ciana, 2005, Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy, J Inherit Metab Dis, 28, 723, 10.1007/s10545-005-0032-y Ciana, 2003, Bone marker alterations in patients with type 1 Gaucher disease, Calcif Tissue Int, 72, 185, 10.1007/s00223-001-2072-0 Drugan, 2002, Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease, Blood Cells Mol Dis, 28, 13, 10.1006/bcmd.2001.0479 Michelin, 2004, Biochemical study on beta-glucosidase in individuals with Gaucher's disease and normal subjects, Clin Chim Acta, 343, 145, 10.1016/j.cccn.2004.01.010 Hollack, 1994, Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease, J Clin Invest, 93, 1288, 10.1172/JCI117084 Giraldo, 2012, Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula, Orphanet J Rare Dis, 7, 17, 10.1186/1750-1172-7-17 Mikosch, 2008, Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat, Calcif Tissue Int, 83, 43, 10.1007/s00223-008-9143-4 Henriksen, 2007, Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases, Osteopor Int, 18, 681, 10.1007/s00198-006-0286-8